Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 95 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: norgestrel Clear all

Conditions: Drug Interactions
Interventions: BIIB074, OC (ethinyl estradiol and levonorgestrel); Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Postpartum
Interventions: Offer of Participant's Choice of Contraception Method; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 15 Years to 35 Years · Female only
Enrollment: 208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Healthy Volunteer
Interventions: Ethinyl Estradiol + Levonorgestrel, ABBV-722; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Contraception
Interventions: AG200-15, Levora; Drug
Lead sponsor: Agile Therapeutics; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 407 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 21
States / cities: Mobile, Alabama • Green Valley, Arizona • Tucson, Arizona + 16 more

Conditions: Breakthrough Bleeding
Interventions: DR-1031, Seasonale®, Portia®; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 567 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 50
States / cities: Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 45 more

Conditions: Menstruation Disturbances, Premenstrual Syndrome
Interventions: levonorgestrel/ethinyl estradiol; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 744 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 69
States / cities: Scottsdale, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 61 more

Conditions: Healthy Participants
Interventions: Povorcitinib, Levonorgestrel/Ethinyl estradiol; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Epilepsy, Contraception
Interventions: levonorgestrel IUS; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV, Immune Cells (Mucosal and Systemic), Contraception
Interventions: levonorgestrel exposure, DMPA exposure, etonogestrel exposure, IUD insertion, subdermal contraceptive implant insertion; Drug · Device
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 34 Years · Female only
Enrollment: 326 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pregnancy Prevention
Interventions: Levonorgestrel 1.5 milligram, Meloxicam 15 milligram, calcium carbonate 750 milligram; Drug · Other
Lead sponsor: InnovaGyn, Inc.; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Menorrhagia
Interventions: Levonorgestrel IUS (Mirena, BAY86-5028), Medroxyprogesterone acetate; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 37
States / cities: Tucson, Arizona • Beverly Hills, California • Carmichael, California + 32 more

Conditions: Contraception
Interventions: Lidocaine, Lubricant; Drug
Lead sponsor: University of Tennessee; Other
Eligibility: Female only
Enrollment: 210 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Chattanooga, Tennessee

Conditions: Contraception
Interventions: Ulipristal Acetate, Levonorgestrel; Drug
Lead sponsor: Kimberly Myer; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 532 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 18
States / cities: Los Angeles, California • Sacramento, California • San Francisco, California + 14 more

Conditions: Healthy
Interventions: Seasonale [levonorgestrel (LNG)/ethinyl estradiol (EE)], Seasonique (LNG/EE and EE), Portia (LNG/EE); Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Contraception
Interventions: Ulipristal Acetate, Levonorgestrel (LNG)/Ethinyl estradiol birth control pill; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Anorexia Nervosa
Interventions: Hormone replacement therapy (estrogen/progestin), Placebo (Sugar Pill), Dehydroepiandrosterone (DHEA); Drug · Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 15 Years to 30 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity
Interventions: Levonorgestrel 1.5mg by mouth once; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Dysmenorrhea
Interventions: levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets, levonorgestrel/EE 0.15/0.03 mg tablets and placebo; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 18
States / cities: Huntsville, Alabama • Phoenix, Arizona • San Diego, California + 14 more

Conditions: HIV Infections, Tuberculosis
Interventions: Levonorgestrel (LNG); Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 16 Years and older · Female only
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 7
States / cities: Chicago, Illinois • New York, New York • Chapel Hill, North Carolina + 3 more

Conditions: Contraception
Interventions: Placebo Control (Placebo Herb), St. John's Wort, Levonorgestrel; Dietary Supplement · Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 30 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Atopic Dermatitis
Interventions: PF-08049820, Midazolam, Dabigatran Etexilate, Portia (EE and LN) or equivalent oral tablet; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Ovarian Carcinoma
Interventions: Laboratory Biomarker Analysis, Levonorgestrel, Placebo; Other · Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 30 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 66
States / cities: Duarte, California • Los Angeles, California • Orange, California + 46 more

Conditions: Endometriosis
Interventions: Placebo, Levonorgestrel, Anastrozole, Lupron / Leuprolide acetate; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 25
States / cities: San Diego, California • San Francisco, California • Gainesville, Florida + 22 more

Conditions: Dyslipidaemia
Interventions: AZD0780, Itraconazole, Carbamazepine, Midazolam, Ethinyl estradiol/levonorgestrel; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Brooklyn, Maryland

Search by objective public record fields.

A Drug Interaction Study of BIIB074 and an Oral Contraceptive Regimen

Home-based Delivery of the Contraceptive Implant in Postpartum Guatemalan Women

A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants

Transdermal Contraceptive Delivery System (TCDS), Also Known as AG200-15 Patch Arm

A Study to Evaluate Bleeding Patterns With Three Different Doses of DR-1031 Compared to Seasonale

Study Evaluating Combination of Levonorgestrel (LNG) and Ethinyl Estradiol (EE) in Premenstrual Dysphoric Disorder

A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females

Women With Epilepsy: a Pilot Study of PK and PD Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users

Quantification of Immune Cells in Women Using Contraception (CHIC II)

Phase II Study of Ovulation in Obese Women

Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS)

Topical Lidocaine on the Cervix and Intra-Cervical Prior to Insertion of Intrauterine Devices

Study Comparing Emergency Contraception Effectiveness in Women Who Weight ≥ 80 kg

A Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Oral Contraceptive Regimens

Impact of Combined Hormonal Contraceptives on UPA

Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa

Effects of Obesity on Pharmacokinetics of the Levonorgestrel Emergency Contraceptive Pill

A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain

Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy

Effects of St. John's Wort on the Oral Contraceptive Hormone Levonorgestrel

A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer

Bay98-7196, Dose Finding / POC Study

An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions